Alto Neuroscience (NYSE:ANRO) Sets New 1-Year High – Time to Buy?

Alto Neuroscience, Inc. (NYSE:ANRO)’s share price hit a new 52-week high on Tuesday . The company traded as high as $28.85 and last traded at $26.7020, with a volume of 43532 shares changing hands. The stock had previously closed at $28.03.

Analyst Ratings Changes

A number of research firms recently commented on ANRO. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Wedbush raised their price target on Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Chardan Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Finally, Wolfe Research started coverage on Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Alto Neuroscience currently has an average rating of “Moderate Buy” and a consensus target price of $35.25.

Alto Neuroscience Trading Up 0.4%

The stock has a fifty day moving average of $23.04 and a 200-day moving average of $21.07. The company has a market cap of $979.19 million, a PE ratio of -11.53 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Sell-side analysts anticipate that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Commodore Capital LP acquired a new stake in Alto Neuroscience in the 4th quarter worth approximately $32,453,000. Perceptive Advisors LLC raised its stake in shares of Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after buying an additional 1,629,027 shares during the last quarter. Vestal Point Capital LP raised its position in Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after acquiring an additional 1,535,000 shares in the last quarter. Spruce Street Capital LP increased its holdings in shares of Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after purchasing an additional 1,102,366 shares in the last quarter. Finally, Vivo Capital LLC acquired a new position in shares of Alto Neuroscience in the fourth quarter worth about $18,433,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.